Phase 3 trial assessing therapy for post-liver transplant HCV initiated Healio Biotest AG has initiated treatment in a phase 3 clinical trial in North America of a therapy for patients who require liver transplantation because of hepatitis C infection, according to a press release. The phase 3 trial will assess the efficacy ... |
